Maxillary Mucormycosis Osteomyelitis in Post COVID-19 Patients: A Series of Fourteen Cases

During the current pandemic of COVID-19, numerous manifestations and complications have developed. Patients with COVID-19 are at high risk of fungal infections, such as mucormycosis, that may result directly from COVID-19 infection and/or as a side effect of the drugs used in COVID-19 treatment prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Said Ahmed, Wael M., Elsherbini, Amira M., Elsherbiny, Nehal M., El-Sherbiny, Mohamed, Ramzy, Nevine I., Arafa, Ahmed F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624954/
https://www.ncbi.nlm.nih.gov/pubmed/34829397
http://dx.doi.org/10.3390/diagnostics11112050
Descripción
Sumario:During the current pandemic of COVID-19, numerous manifestations and complications have developed. Patients with COVID-19 are at high risk of fungal infections, such as mucormycosis, that may result directly from COVID-19 infection and/or as a side effect of the drugs used in COVID-19 treatment protocol, such as dexamethasone, hydroxychloroquine, and antibiotics. In this report, we described a series of 14 cases with maxillary mucormycosis osteomyelitis in immediate post-COVID-19 patients.

Ejemplares similares